ProQR Therapeutics N.V. Ordinary Shares
PRQRStock
$1.67−25.00%52W
Market Cap$279.82M
P/E—
Div yield—
Beta-0.01
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-27.52%
Price vs S&P 500 (4W)15.85%
VGM Score38.81
Market Capitalization$279.82M
Earnings Surprise History
Q1 26-0.15est. -0.14
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.27
4.27
4.27
4.27
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PRQRProQR Therapeutics N.V. Ordinary Shares | C | D | C | $1.67 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
ProQR Therapeutics NV develops RNA-based therapeutics for severe genetic rare diseases, including cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The company's entire research and development effort is dedicated to discovering and advancing RNA therapeutics.